pyridoxine has been researched along with Vascular Diseases in 24 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency leads to severe hyperhomocysteinemia (HHcy)." | 8.80 | Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. ( Boers, GH; Naughten, ER; Wilcken, B; Wilcken, DE; Yap, S, 2000) |
| "Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency leads to severe hyperhomocysteinemia (HHcy)." | 4.80 | Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. ( Boers, GH; Naughten, ER; Wilcken, B; Wilcken, DE; Yap, S, 2000) |
| "Using an atherogenic diet that produces both hyperhomocysteinemia and hypercholesterolemia, we tested the hypothesis that dietary supplementation with B vitamins (folic acid, vitamin B(12), and vitamin B(6)) would prevent hyperhomocysteinemia, vascular dysfunction, and atherosclerotic lesions in monkeys." | 3.71 | Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. ( Heistad, DD; Lentz, SR; Malinow, MR; Piegors, DJ, 2001) |
| " Different shapes of the dose-response relationship were seen for the 3 vascular disease categories." | 1.31 | Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. ( El-Khairy, L; Graham, IM; Refsum, H; Ueland, PM; Vollset, SE, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (29.17) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| BRANZI, G | 1 |
| ANNINO, G | 1 |
| GRESHAM, GA | 1 |
| Jamison, RL | 1 |
| Hartigan, P | 1 |
| Kaufman, JS | 1 |
| Goldfarb, DS | 1 |
| Warren, SR | 1 |
| Guarino, PD | 1 |
| Gaziano, JM | 1 |
| Franken, DG | 1 |
| Boers, GH | 4 |
| Blom, HJ | 1 |
| Trijbels, JM | 1 |
| Nicolas, JP | 1 |
| Chango, A | 1 |
| Robinson, K | 2 |
| Arheart, K | 1 |
| Refsum, H | 2 |
| Brattström, L | 1 |
| Boers, G | 1 |
| Ueland, P | 1 |
| Rubba, P | 1 |
| Palma-Reis, R | 1 |
| Meleady, R | 2 |
| Daly, L | 1 |
| Witteman, J | 1 |
| Graham, I | 1 |
| Wilcken, DE | 2 |
| Czeizel, AE | 1 |
| Merhala, Z | 1 |
| Hockly, E | 1 |
| Brown, MJ | 1 |
| Verhoef, P | 1 |
| Daly, LE | 1 |
| Graham, IM | 2 |
| Constans, J | 1 |
| Blann, AD | 1 |
| Resplandy, F | 1 |
| Parrot, F | 1 |
| Renard, M | 1 |
| Seigneur, M | 1 |
| Guérin, V | 1 |
| Boisseau, M | 1 |
| Conri, C | 1 |
| Cella, G | 1 |
| Burlina, A | 1 |
| Sbarai, A | 1 |
| Motta, G | 1 |
| Girolami, A | 1 |
| Berrettini, M | 1 |
| Strauss, W | 1 |
| Yap, S | 1 |
| Naughten, ER | 1 |
| Wilcken, B | 1 |
| Diaz-Arrastia, R | 1 |
| Saw, SM | 1 |
| Yuan, JM | 1 |
| Ong, CN | 1 |
| Arakawa, K | 1 |
| Lee, HP | 1 |
| Coetzee, GA | 1 |
| Yu, MC | 1 |
| Lentz, SR | 1 |
| Piegors, DJ | 1 |
| Malinow, MR | 1 |
| Heistad, DD | 1 |
| El-Khairy, L | 1 |
| Ueland, PM | 1 |
| Vollset, SE | 1 |
| Miller, JW | 1 |
| Osborne-Pellegrin, MJ | 1 |
| Schwarz, D | 1 |
| Fourrier, A | 1 |
| Mouton, Y | 1 |
| Kim, M | 1 |
| Vérin, P | 1 |
| Yacoubi, M | 1 |
| Morax, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)[NCT00032435] | Phase 3 | 2,003 participants (Anticipated) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pyridoxine and Vascular Diseases
| Article | Year |
|---|---|
Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease.
Topics: Arteriosclerosis; Betaine; Coronary Disease; Folic Acid; Heterozygote; Homocysteine; Homocystinuria; | 1994 |
Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy.
Topics: Adolescent; Adult; Aged; Australia; Child; Child, Preschool; Cohort Studies; Cystine; Drug Resistanc | 2000 |
Homocysteine and neurologic disease.
Topics: Brain Diseases; Epilepsy; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Neurodegenerative | 2000 |
Does lowering plasma homocysteine reduce vascular disease risk?
Topics: Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Pyridoxine; Risk Factors; Vascular Diseases | 2001 |
3 trials available for pyridoxine and Vascular Diseases
| Article | Year |
|---|---|
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
Topics: Aged; Cause of Death; Double-Blind Method; Female; Folic Acid; Homocysteine; Humans; Kaplan-Meier Es | 2007 |
Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinaemia in vascular patients.
Topics: Amino Acid Metabolism, Inborn Errors; Folic Acid; Homocysteine; Humans; Middle Aged; Pyridoxine; Vas | 1994 |
[Clinical and biological study of a new vascular protective agent and hypolipemic agent, pyridoxine para-chloro-phénoxy-isobutyrate. (Claresan)].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Diet, Reducing; Drug Tolerance; Female; Humans; H | 1974 |
17 other studies available for pyridoxine and Vascular Diseases
| Article | Year |
|---|---|
[Therapy of peripheral arteriopathies with a compound with a base of inositol hexanicotinate].
Topics: Inositol; Niacin; Nicotinic Acids; Peripheral Arterial Disease; Peripheral Vascular Diseases; Pyrido | 1963 |
CHOLESTEROL. II. DIET AND ARTERIAL DISEASES.
Topics: Animals; Cholesterol; Coronary Disease; Diet; Diet Therapy; England; Fats; Meat; Poultry; Pyridoxine | 1963 |
[Deregulation of homocysteine metabolism and consequences for the vascular system].
Topics: Folic Acid; Homocysteine; Humans; Pyridoxine; Vascular Diseases; Vitamin B 12 Deficiency | 1997 |
Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group.
Topics: Adult; Analysis of Variance; Arteriosclerosis; Avitaminosis; Case-Control Studies; Cerebrovascular D | 1998 |
Homocysteine and vascular disease.
Topics: Dietary Supplements; Folic Acid; Homocysteine; Humans; Pyridoxine; Risk Factors; Vascular Diseases; | 1998 |
Bread fortification with folic acid, vitamin B12, and vitamin B6 in Hungary.
Topics: Anemia, Pernicious; Bread; Female; Folic Acid; Food, Fortified; Humans; Hungary; Neural Tube Defects | 1998 |
Homocysteine, vitamins and sex.
Topics: Folic Acid; Homocysteine; Humans; Pyridoxine; Sex Factors; Vascular Diseases; Vitamin B 12 | 1999 |
Homocysteine, vitamin status and risk of vascular disease; effects of gender and menopausal status. European COMAC Group.
Topics: Case-Control Studies; Female; Folic Acid; Homocysteine; Humans; Male; Menopause; Pyridoxine; Risk Fa | 1999 |
Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction.
Topics: Adult; Endothelium, Vascular; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Male; | 1999 |
Tissue factor pathway inhibitor levels in patients with homocystinuria.
Topics: Adult; Betaine; Biomarkers; Cystathionine beta-Synthase; Endothelium; Factor VII; Female; Fibrinolyt | 2000 |
Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore.
Topics: Aged; Aging; Asian People; Cohort Studies; Exercise; Female; Folic Acid; Genotype; Homocysteine; Hum | 2001 |
Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys.
Topics: Animals; Arteriosclerosis; Blood Coagulation; Carotid Arteries; Cholesterol; Diet, Atherogenic; Diet | 2001 |
Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project.
Topics: Adult; Case-Control Studies; Creatinine; Cysteine; Female; Folic Acid; Homocysteine; Humans; Logisti | 2001 |
Spontaneous arterial lesions involving breaks in the internal elastic lamina in the rat: effects of beta-aminopropionitrile and familial distribution.
Topics: Age Factors; Aminopropionitrile; Animals; Arteries; Copper; Diet; Endothelium; Female; Male; Pyridox | 1986 |
[Medical therapy of obliterating arteriopathies].
Topics: Arteriosclerosis Obliterans; Diabetic Angiopathies; Gangrene; Humans; Inositol; Niacinamide; Pyridox | 1969 |
[Drugs in syndromes of dysfunction of arteriovenous anastomoses].
Topics: Acetylcholine; Animals; Arteriovenous Anastomosis; Epinephrine; Ergoloid Mesylates; Histamine; Human | 1967 |
[Functional deficiencies of the fundus oculi due to vascularization disorders. 81 patients treated with Dilpavan].
Topics: Ascorbic Acid; Eye Diseases; Flavonoids; Fundus Oculi; Humans; Papaverine; Pyridoxine; Vascular Dise | 1971 |